Growing at an annualized rate of over 9%, the antibody discovery

narender.shukla@rootsanalysis.co

257
views

Growing at an annualized rate of over 9%, the antibody discovery services market

Hightarget specificity and favorable safety profiles offered by antibody basedpharmacological interventions has created a high demand for such molecules; thedomain has witnessed an increased inflow of investments and collaborationopportunities.

London

Roots Analysis has announced theaddition of “AntibodyDiscovery: Services and Platforms Market (3rd Edition), 2020-2030” report to its listof offerings.

The development of such biologics is inherentlycomplex, and many drug developers are now seeking to optimize R&Defficiency and affiliated costs. As a result, innovator companies areoutsourcing most of their discovery-stage operations to specialty contractresearch organizations (CROs), which offer a plethora of advanced technologiesto cater to the evolving needs. It is also worth highlighting that stakeholdersengaged in this domain are actively undertaking initiatives to developinterventions for SARS-CoV-2 virus.

To order this 450+ pagereport, which features 120+ figures and 140+ tables, please visit this link

KeyMarket Insights

Presently,more than 80 players claim to offer services for antibody discovery

Over90% of the aforementioned players provide services for hit generation, followedby those offering services for antibody humanization (58%). It is worthmentioning that five service providers claim to have the required expertise toserve as one-stop-shops for all the antibody discovery steps.

More than120 companies offer antibody discovery platforms

It isworth highlighting that close to 180 technologies focused on antibody discoveryare presently available in the market. Further, nearly 50% platforms uselibrary-based methods to discover antibodies. Amongst these, phage display iscurrently the most widely used technique. This is followed by single cell-basedmethods (20%).

Partnershipactivity within this domain has grown at a CAGR of 18%, between 2015 and 2020

In thelast five years, more than 400 agreements were inked related to antibodydiscovery, with the maximum activity being reported in 2018. Majority ofpartnership deals signed within this domain were licensing agreements (25%),product development and commercialization agreements (24%), and R&Dagreements (18%).

Nearly USD 7 billion has been invested in the antibody discoverydomain, during 2016-2020

Theaforementioned amount was raised across more than 140 funding instances. It isimportant to mention that, in 2019-2020, over USD 2 billion was raised byantibody discovery service and platform providers across close to 40 instances.Majority of the funding in this year was acquired through venture capitalrounds (42%), grants (20%), and instances of initial public offering (10%).

Theantibody discovery services market is anticipated to be worth over USD 6billion by 2030

Majority of the market opportunity (60%) is expectedto be generated from antibody services offered through phage display andhybridoma based methods, followed by those using transgenic animal basedmethods; this trend is unlikely to change in the foreseen future as well.

Thelicensing market opportunity for antibody discovery platforms is anticipated togrow at a CAGR of close to 10%, during 2020-2030

By 2030, NorthAmerica is estimated to capture over 50% (in terms of revenues generated)share of the antibody discovery platforms market.It is worth mentioning that the market for antibody discovery platforms in Asia-pacificis anticipated to grow at a relatively faster pace, during the forecast period.

To request a sample copy /brochure of this report, please visit this link

Key Questions Answered

§ Who are the leading players engagedin offering services and platforms for antibody discovery?

§ What are the most popular typesof services offered for antibody discovery?

§ Who are the key opinion leadersfrom renowned academic and research institutes that can help you drive efforts relatedto antibody discovery?

§ What is the trend of capitalinvestments being made in the antibody discovery market?

§ Which partnership models are mostcommonly adopted by stakeholders engaged in this industry?

§ What are the opportunities forantibody discovery service and platform providers in emerging markets?

§ How is the current and futureopportunity likely to be distributed across key market segments?

The USD 6.5billion (by 2030) financial opportunity within the antibody discovery services markethas been analyzed across the following segments:

§ Steps Involved in theAntibody Discovery Process

Antigen Designing
Hit Generation
Lead Selection
Lead Optimization
Lead Characterization

§ Antibody DiscoveryMethod Used

Phage Display
Hybridoma
Transgenic Animal
Yeast Display
Single Cell
Others

§ Nature of AntibodyGenerated

Humanized
Human
Chimeric
Murine

§ Key GeographicalRegions

North America
Europe
Asia Pacific and Rest of the World

The USD 5.9billion (by 2030) financial opportunity within the antibody discovery platformsmarket has been analysed across the following segments:

§ Type of Payment

Upfront Payments
Milestone Payments

§ Key GeographicalRegions

North America
Europe
Asia Pacific

Thereport features inputs from eminent industry stakeholders, according to whom, inthe foreseen future, competition within antibody discovery services and platforms is expected to growsignificantly, resulting in an increase in the overall market value. The reportincludes detailed transcripts of discussions held with the following experts:

§ Tracey Mullen (Chief ExecutiveOfficer, Abveris Antibody)

§ Lisa Delouise (Founder and ChiefTechnology Officer, Nidus Biosciences)

§ Mark Kubik (Chief BusinessOfficer, AvantGen)

§ Chun-Nan Chen (Chief ExecutiveOfficer and Chief Scientific Officer, Single Cell Technology)

§ Giles Day (Co-Founder and ChiefExecutive Officer, Distributed Bio)

§ Kevin Heyries (Co-Founder andLead of Business Development Strategy, AbCellera)

§ Sanjiban K Banerjee (Director, AbGenics Life Sciences)

§ Ignacio Pino (Chief ExecutiveOfficer and President, CDI Laboratories)

§ Jeng Her (Chief ExecutiveOfficer, APBiosciences)

§ Thomas Schirrmann (ChiefExecutive Officer and General Manager, YUMAB)

§ Debra Valsamis (BusinessDevelopment Associate, Antibody Solutions)

§ Christel Iffland (Vice President,Ligand Pharmaceuticals)

§ Aaron Sato (former ChiefScientific Officer, LakePharma)

Theresearch includes detailed profiles of key players (listed below); eachprofile features an overview of the company, its financial information (if available), a descriptionof the platform(s) / service(s) offered, details of recent developments relatedto antibody discovery and an informed future outlook.

§ Abzena

§ Abwiz Bio

§ Aragen Bioscience

§ BIOTEM

§ ChemPartner

§ Creative Biolabs

§ Distributed Bio

§ Harbour BioMed

§ HD Biosciences

§ ImmunoPrecise Antibodies

§ Integral Molecular

§ Kymab